Cancer Biomarker Discovery and Verification for Immuno-Oncology Research

Characterizing tumor microenvironment biomarkers

Thermo Fisher Scientific offers the right solution for immuno-oncology related applications to help enable scientists to accelerate their research and discovery of new therapies. Discovery and development of effective cancer immunotherapy requires a better understanding of the cellular and biochemical makeup where a tumor resides, or in its microenvironment. The tumor microenvironment is a result of the physiology, the immune system, and the associated cellular and molecular factors. Dissecting the stages of tumorigenesis, from onset through cellular transformation and metastasis, requires a comprehensive knowledge of the tumor microenvironment.

Knowledge of these complex dynamics within in the cellular microenvironment is the basis for identifying a tumor’s unique biosignature, and consequently its nature. A tumor’s biosignature is the result of its relationship with the organ, tissue, or cells with which it interacts, as well as growth factors and chemokines/cytokines that affect signaling cascades. For instance, there is mounting evidence that tissue infiltrating inflammatory cells and their chemical mediators contribute to deleterious alterations in DNA, RNA, proteins, lipids, and metabolites, leading to dysregulation of normal cellular processes. Consequently, cell cycle, apoptosis, intercellular and intracellular signaling cascades are affected, often resulting in tumor formation. It is thus crucial to identify biomarkers that will pinpoint key features of a tumor that are responsible for tumorigenesis. Cancer with its many forms and unique molecular traits remains difficult to investigate without the appropriate tools. Thermo Fisher Scientific offers traditional as well as the next generation of genomic and proteomic tools for studying, analyzing, and correlating the complex interactions between the immune system, tumor, and tumor microenvironment.

Thermo Fisher Scientific can help support your cancer biomarker discovery and verification studies across key immuno-oncology research areas including CAR T-cell therapy, cancer vaccine, and checkpoint inhibitor therapy research. We have the portfolio breadth so that cancer researchers can select the right solution for a specific application, including:

Proteomic biomarker discovery and verification

Antibodies

Search our extensive portfolio of antibodies to key checkpoint markers, including:

• CTLA-4
• PD-1
• PD-L1
• TIM-1
• LAG-3
• BTLA

Quantitative protein analysis

We offer quality Invitrogen immunoassays designed to help you easily quantify checkpoint protein biomarkers with confidence.

Singleplex quantitation of proteomic biomarkers

• Validated ELISA kits—complete and ready to use, designed to enable accurate protein quantitation of immune-related cancer targets. We also offer simplified workflow and high-sensitivity options.
• Robust, reliable microplate readers—from the original inventors of microplate readers, choose from a lineup of tried and true Thermo Scientific dedicated and multimode readers, all powered by the same intuitive SkanIt Software.
• ProQuantum Immunoassays—when working with very limited samples, this unique platform offers high-sensitivity with a streamlined workflow, available with popular targets used in I/O research.

Multiplex quantitation of proteomic biomarkers

• ProcartaPlex preconfigured panels—profile more biomarkers simultaneously, save time and sample
• Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 1—custom mix for I/O research
• Immuno-Oncology Checkpoint 14-Plex Human ProcartaPlex Panel 2—custom mix for I/O research
• ProcartaPlex panel configurator tool—choose your specific I/O targets and have us blend and validate a custom multiplex panel for you with up to 80 analytes